Literature DB >> 23907513

Optimization of storage and manufacture conditions for imidapril hydrochloride in solid state as a way to reduce costs of antihypertensive therapy.

Katarzyna Regulska1, Beata Stanisz, Paweł Lisiecki.   

Abstract

The effect of temperature and relative humidity (RH) on the stability of imidapril hydrochloride (IMD) in solid state was investigated. The main aim of this study was to determine the most appropriate conditions of storage and manufacture of IMD so that the efficiency of the technological process could be improved and its costs could be minimized. A reversed-phase high-performance liquid chromatography was validated and applied for the determination of IMD degradation samples under the following operating conditions: stationary phase, LiChrospher 100 RP-18 (size 5 μm) 250 × 4 mm I.D., and mobile phase, acetonitrile-methanol-phosphate buffer, pH 2.0, 0.035 mol L(-1) (60:10:30 v/v/v). The effect of temperature on IMD degradation rate was analyzed under increased RH ≈ 76.4% (within temperature range of 70-90°C) and decreased RH ≈ 0% (within temperature range of 90-110°C). The influence of RH was investigated under 90°C within RH range of 25.0-76.4%. IMD degradation accords with autocatalytic reaction model, and RH has no influence on its mechanism yet it increases its rate. The reaction also accelerates under high temperatures and in the presence of IMD degradation product. Pure IMD is more stable than other structurally related angiotensin-converting enzyme inhibitors, such as enalapril maleate, but it still should be stored in tightly closed containers and protected from moisture and high temperatures.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23907513      PMCID: PMC3755141          DOI: 10.1208/s12249-013-0010-x

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  11 in total

1.  Evaluation of stability of enalapril maleate in solid phase.

Authors:  Beata Stanisz
Journal:  J Pharm Biomed Anal       Date:  2003-02-26       Impact factor: 3.935

2.  Determination of three metabolites of a new angiotensin-converting enzyme inhibitor, imidapril, in plasma and urine by gas chromatography-mass spectrometry using multiple ion detection.

Authors:  M Matsuoka; S Horimoto; M Mabuchi; K Banno
Journal:  J Chromatogr       Date:  1992-10-02

3.  The stability of quinapril hydrochloride--a mixture of amorphous and crystalline forms (QHCl-AC)--in solid phase.

Authors:  Beata Stanisz
Journal:  Acta Pol Pharm       Date:  2003 Nov-Dec       Impact factor: 0.330

Review 4.  Solid-state kinetic models: basics and mathematical fundamentals.

Authors:  Ammar Khawam; Douglas R Flanagan
Journal:  J Phys Chem B       Date:  2006-09-07       Impact factor: 2.991

5.  UV derivative spectrophotometric and RP-HPLC methods for determination of imidapril hydrochloride in tablets and for its stability assessment in solid state.

Authors:  Beata Stanisz; Katarzyna Regulska; Kinga Kolasa
Journal:  Acta Pol Pharm       Date:  2011 Sep-Oct       Impact factor: 0.330

6.  Effect of pharmaceutical excipients on the stability of angiotensin-converting enzyme inhibitors in their solid dosage formulations.

Authors:  Beata Stanisz; Katarzyna Regulska; Jagoda Kania; Piotr Garbacki
Journal:  Drug Dev Ind Pharm       Date:  2012-02-20       Impact factor: 3.225

7.  Radioimmunoassay for imidapril, a new angiotensin-converting enzyme inhibitor, and imidaprilat, its active metabolite, in human plasma and urine.

Authors:  K Yamanaka; S Morikawa; K Murata; K Banno; T Sato; T Takai; T Suzuki; M Mizobe; M Ito; K Ishibashi
Journal:  J Pharm Biomed Anal       Date:  1996-01       Impact factor: 3.935

8.  Kinetics of degradation of quinapril hydrochloride in tablets.

Authors:  B Stanisz
Journal:  Pharmazie       Date:  2003-04       Impact factor: 1.267

9.  Imidapril hydrochloride in essential hypertension: a double-blind comparative study using enalapril maleate as a control.

Authors:  T Saruta; T Omae; M Kuramochi; O Iimura; K Yoshinaga; K Abe; M Ishii; T Watanabe; T Takeda; K Ito
Journal:  J Hypertens Suppl       Date:  1995-09

Review 10.  Role of renin angiotensin system inhibitors in cardiovascular and renal protection: a lesson from clinical trials.

Authors:  Ljuba Stojiljkovic; Rahim Behnia
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

View more
  4 in total

1.  Visualization of the photodegradation of a therapeutic drug by chemometric-assisted fluorescence spectroscopy.

Authors:  Masaru Tanioka; Tsugumi Ebihana; Manae Uraguchi; Haruka Shoji; Yuka Nakamura; Rina Ueda; Shota Ogura; Yoshifumi Wakiya; Tohru Obata; Takahiro Ida; Jun Horigome; Shinichiro Kamino
Journal:  RSC Adv       Date:  2022-07-19       Impact factor: 4.036

2.  The mutagenicity analysis of imidapril hydrochloride and its degradant, diketopiperazine derivative, nitrosation mixtures by in vitro Ames test with two strains of Salmonella typhimurium.

Authors:  Katarzyna Regulska; Marek Murias; Beata Stanisz; Miłosz Regulski
Journal:  Rep Pract Oncol Radiother       Date:  2014-05-02

3.  Thermo-, Radio- and Photostability of Perindopril Tert-butyloamine in The Solid State. Comparison to Other Angiotensin Converting Enzyme Inhibitors.

Authors:  Anna Wzgarda; Katarzyna Dettlaff; Martyna Rostalska; Ewa Pabian; Katarzyna Regulska; Beata Jadwiga Stanisz
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

4.  Lignin-Based Spherical Structures and Their Use for Improvement of Cilazapril Stability in Solid State.

Authors:  Małgorzata Stanisz; Łukasz Klapiszewski; Dariusz T Mlynarczyk; Beata J Stanisz; Teofil Jesionowski
Journal:  Molecules       Date:  2020-07-09       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.